NEW YORK (GenomeWeb News) – NextBio and Genophen today said they are partnering to drive adoption of genomics for disease prevention and wellness.
They said the deal allows Genophen to interpret genomic sequencing data from patients through the use of NextBio's clinical platform and to combine this information with data about a patient's environmental, behavioral, and clinical factors "to create a uniquely tailored disease prevention and wellness plan for its individual member."
Financial and other terms of the deal were not disclosed.
"NextBio's vast and comprehensive repository of curated genomic and clinical data from the public domain adds depth to our analysis," Hossein Fakhrai-Rad, co-founder, president, and CEO of Genophen, said in a statement. "This partnership with NextBio Clinical enables us to efficiently analyze and interpret whole-genome data."
NextBio, based in Santa Clara, Calif., provides tools for the interpretation of large amounts molecular and other life sciences data.
Genophen is headquartered in Los Altos, Calif., and has developed a software platform for assessing a patient's disease risk, providing a personalized and actionable set of recommendations, it said.